Stephanie Popping Selected Research

Chronic Hepatitis C

1/2019

Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephanie Popping Research Topics

Disease

8	Infections 07/2023 - 01/2018
5	Hepatitis C 05/2022 - 07/2018
1	COVID-19 07/2023
1	Neoplasms (Cancer) 07/2023
1	Liver Cirrhosis (Hepatic Cirrhosis) 06/2021
1	Chronic Hepatitis C 01/2019
1	Persistent Infection 01/2019
1	Fibrosis (Cirrhosis) 01/2019

Drug/Important Bio-Agent (IBA)

9	Antiviral Agents (Antivirals)IBA 05/2022 - 01/2018
1	Monoclonal AntibodiesIBA 07/2023
1	AntigensIBA 11/2019
1	Alanine Transaminase (SGPT)IBA 11/2019
1	grazoprevirIBA 01/2019
1	elbasvirIBA 01/2019

Therapy/Procedure

1	Transplantation 07/2023
1	Treatment Delay 01/2019
1	Therapeutics 01/2019